FDA approves Horizant to treat restless legs syndrome

Posted by (author unknown) on Thursday Apr 7, 2011 Under Uncategorized

On April 6, the U.S. Food and Drug Administration approved Horizant Extended Release Tablets (gabapentin enacarbil), a once-daily treatment for moderate-to-severe restless legs syndrome (RLS).

Be Sociable, Share!

Comments are closed.